Developmental and Epileptic Encephalopathy 6A clinical trials
12 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
- Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
- ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
- A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
- The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
- GABA Biomarkers in Dravet Syndrome
- CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
- Early Check: Expanded Screening in Newborns
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Developmental and Epileptic Encephalopathy 6A” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.